These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1356530)

  • 21. Treatment of Chinese acromegaly with a combination of bromocriptine and octreotide.
    Li JK; Chow CC; Yeung VT; Mak TW; Ko GT; Swaminathan R; Chan JC; Cockram CS
    Aust N Z J Med; 2000 Aug; 30(4):457-61. PubMed ID: 10985510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects.
    Halse J; Harris AG; Kvistborg A; Kjartansson O; Hanssen E; Smiseth O; Djøsland O; Hass G; Jervell J
    J Clin Endocrinol Metab; 1990 May; 70(5):1254-61. PubMed ID: 2186055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly.
    Catnach SM; Anderson JV; Fairclough PD; Trembath RC; Wilson PA; Parker E; Besser GM; Wass JA
    Gut; 1993 Feb; 34(2):270-3. PubMed ID: 8432484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatostatin analogue (SMS 201-995) in resistant acromegaly: a preliminary report.
    Atkinson AB; McKnight JA; McCance DR; Bell PM
    Horm Res; 1990; 33 Suppl 1():7-11; discussion 11-2. PubMed ID: 2358295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.
    Turner HE; Lindsell DR; Vadivale A; Thillainayagam AV; Wass JA
    Eur J Endocrinol; 1999 Dec; 141(6):590-4. PubMed ID: 10601961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of biliary lithogenesis in acromegalic patients with long-term octreotide (SMS 201-995) treatment].
    Buscail LE; Puel-Bousquet C; Harris AG; Tauber JP; Escourrou JR; Delvaux MM; Vaysse NM; Bayard F; Ribet A
    Gastroenterol Clin Biol; 1991; 15(11):800-4. PubMed ID: 1769469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Octreotide treatment of acromegaly.
    Wass JA
    Horm Res; 1990; 33 Suppl 1():1-5; discussion 6. PubMed ID: 2358294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management.
    Redfern JS; Fortuner WJ
    Am J Gastroenterol; 1995 Jul; 90(7):1042-52. PubMed ID: 7611194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly.
    Stolk MF; van Erpecum KJ; Koppeschaar HP; de Bruin WI; Jansen JB; Lamers CB; van Berge Henegouwen GP
    Gut; 1993 Jun; 34(6):808-13. PubMed ID: 8314514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medical management of acromegaly--what and when?
    Melmed S
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():13-7. PubMed ID: 8372605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones.
    Hussaini SH; Pereira SP; Veysey MJ; Kennedy C; Jenkins P; Murphy GM; Wass JA; Dowling RH
    Gut; 1996 May; 38(5):775-83. PubMed ID: 8707128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly.
    de Herder WW; Uitterlinden P; van der Lely AJ; Hofland LJ; Lamberts SW
    Eur J Endocrinol; 1995 Aug; 133(2):195-9. PubMed ID: 7544670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue.
    Yang IM; Woo JT; Kim SW; Kim JW; Kim YS; Choi YK
    Clin Endocrinol (Oxf); 1995 Mar; 42(3):295-301. PubMed ID: 7758235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly.
    Plöckinger U; Dienemann D; Quabbe HJ
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1658-62. PubMed ID: 2229321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of Sandostatin in acromegaly.
    Sassolas G
    Metabolism; 1992 Sep; 41(9 Suppl 2):39-43. PubMed ID: 1518432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [An observation of the secretion of growth hormone and contraction of gall bladder after long-term use of growth-inhibition excitants].
    Zhu XF; Shi YF; Gao SM
    Zhonghua Nei Ke Za Zhi; 1994 Feb; 33(2):87-91. PubMed ID: 8070297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML; Harris AG
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
    Shi YF; Harris AG; Zhu XF; Deng JY
    Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
    Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
    Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.